Sanofi eczema drug weighed down by mixed results, safety concerns [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Dive Brief: Sanofi disappointed some on Wall Street with its latest look at an experimental eczema drug that the French pharmaceutical giant has pegged as a potential blockbuster. On Saturday, Sanofi said the drug, amlitelimab, met the primary endpoints of two late-stage studies titled COAST 1 and COAST 2. These experiments tested amlitelimab by itself, across two different dosing regimens, in patients aged 12 and older who have moderate-to-severe atopic dermatitis. After 24 weeks of treatment, amlitelimab met the main goals of both trials — which, for the U.S. and other countries where similar regulatory expectations apply, focused on the proportion of patients whose skin was deemed “clear” or “almost clear” and had improved by at least two points on a five-point scale researchers use to assess the severity of eczema. However, COAST 2 did not meet statistical significance on co-primary endpoints meant for the for the European Union and its reference countries. A third trial du
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal [Yahoo! Finance]Yahoo! Finance
- Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host diseaseGlobeNewswire
- Sanofi Oncology And Rare Disease Updates Spark Fresh Valuation Interest [Yahoo! Finance]Yahoo! Finance
- Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 3/31/26 - Form 6-K
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- SNY's page on the SEC website